Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors

NCT03811652 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT03811652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03811652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI7247 in Patients With Advanced or Metastatic Disease in Selected Solid Tumors
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
December 20, 2018
Completion date
December 10, 2019
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (crc), head and neck squamous cell carcinoma (hnscc), metastatic castration-resistant prostate cancer (mcrpc), non small cell lung cancer squamous (nsclc-sq), pancreatic ductal adenocarcinoma (pdac), small cell lung cancer (sclc)